Off-label prescriptions for atopic dermatitis in Europe
Authors:
Abstract
Moderate-to-severe forms of atopic dermatitis (AD) have a substantial impact on the quality of life of patients and their relatives, carrying a significant socioeconomic burden. They often require a systemic therapy, and ciclosporine A (CsA) is the only medicinal product approved for this indication in a limited number of European countries. However, due to the safety profile of CsA and its approval conditions, this treatment can only be prescribed for a limited period of time. Thus, moderate-to-severe forms of AD represent a significant unmet medical need and are subject to off-label prescriptions. Besides giving some insights into the approval procedures for medicinal products in the European Union, this short review is aimed to provide some relevant background information for off-label prescription in AD. It also provides a clinical algorithm for the off-label prescription of systemic immunosuppressants in AD, discusses the apparent dilemma between approval and guidelines, and finally suggests practical rules to be considered in the context of off-label prescription.Keywords
Funding Information
- CK-Care
This publication has 33 references indexed in Scilit:
- Willingness to pay and quality of life in patients with atopic dermatitisArchives of Dermatological Research, 2013
- Immunology of atopic eczema: overcoming the Th1/Th2 paradigmAllergy, 2013
- Structural Basis of Signaling Blockade by Anti-IL-13 Antibody LebrikizumabJournal of Molecular Biology, 2013
- Systemic Treatment of Pediatric Atopic Dermatitis with Azathioprine and Mycophenolate MofetilPediatric Dermatology, 2011
- Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot studyJournal of Allergy and Clinical Immunology, 2011
- Japanese Guideline for Atopic DermatitisAllergology International, 2011
- Recalcitrant Atopic Dermatitis Treated with OmalizumabAnnals of Dermatology, 2010
- Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus ReportAllergy, 2006
- Guidelines of care for atopic dermatitisJournal of the American Academy of Dermatology, 2004
- The cost of atopic eczemaBritish Journal of Dermatology, 1996